9月29日，英派药业-B盘中上涨8.26%，报14.03港元，成交额5400.01万港元，此前该股曾一度回调逾10%后企稳反弹。
消息面上，公司核心产品塞纳帕利近期获欧洲药品管理局人用药品委员会（CHMP）积极意见，建议批准其用于晚期上皮性卵巢癌等维持治疗的上市许可，后续将提交欧盟委员会作出最终决定，一旦获批将可在所有欧盟成员国及欧洲经济区国家上市销售。此外，公司此前已与Pharmanovia达成独家授权协议，覆盖欧洲、中东、北非等地区，最高交易对价达4.235亿欧元。叠加9月7日正式纳入港股通、上半年营收同比增长316.8%至1.05亿元及CEO蔡遂雄公开市场增持等多重利好，市场情绪持续修复。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.